• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America
ConclusionsXANTUS-EL confirmed low stroke and major bleeding rates in patients with NVAF from EEMEA and Latin America. The population was younger but with more heart failure and hypertension than XANTUS; stroke/SE rate was similar but major bleeding lower.
Source: The Egyptian Heart Journal - October 5, 2018 Category: Cardiology Source Type: research

Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real life study.
Abstract Our objective was to assess the association between reduced apixaban dose and two outcomes: ischemic stroke/systemic embolism (SE) and major bleeding. We performed a retrospective cohort study within the database of the largest healthcare provider in Israel. We identified all patients diagnosed with atrial fibrillation, who started apixaban treatment between 2013 and 2017. Apixaban users were classified into three dosing regimen groups based on their renal function, age and weight: standard dose (5 mg bid), adjusted reduced dose (2.5 mg bid), and underdosing (2.5 mg bid). Patients were followed through 2...
Source: Clinical Pharmacology and Therapeutics - June 18, 2020 Category: Drugs & Pharmacology Authors: Salameh M, Gronich N, Stein N, Kotler A, Rennert G, Auriel E, Saliba W Tags: Clin Pharmacol Ther Source Type: research

Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-Treated Patients
Clin Ther. 2023 Jan 16:S0149-2918(22)00416-7. doi: 10.1016/j.clinthera.2022.12.010. Online ahead of print.ABSTRACTPURPOSE: In clinical studies, rivaroxaban treatment has been associated with increased incidence of syncope not related to bleeding, anemia, or stroke. The study objective was to evaluate the occurrence of dizziness and/or syncope not related to bleeding, anemia, or stroke in patients treated with direct oral anticoagulants (DOACs).METHODS: A retrospective, observational, comparative study of adult patients diagnosed with atrial fibrillation and treated with DOACs was conducted using digital retrieval of medica...
Source: Clinical Therapeutics - January 18, 2023 Category: Drugs & Pharmacology Authors: Ophir Lavon Daisy Cohen Source Type: research

Direct Oral Anticoagulants and Mortality in Atrial Fibrillation
ConclusionsIn this cohort of newly diagnosed NVAF patients treated in routine clinical practice, DOAC therapy was associated with a lower risk for death compared to no oral anticoagulation. Our findings provide further evidence for the importance of DOAC therapy in NVAF patients.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ellis, M., Ruslan, S., Ariel, H., Greenberg-Dotan, S., Battat, E., Hamburger-Avnery, O., Greenberg, D., Ronen, A. Tags: 332. Antithrombotic Therapy Source Type: research

Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: a population ‐based study
ConclusionIn this real world, population ‐based cohort of patients with newly diagnosed AF, we found a lower than expected rate of OAC prescription within 3 months of diagnosis but an encouraging increase in OAC purchasing over time. Use of NOACs has risen exponentially in only a few years, accounting for a greater pool of AF patients be ing prescribed an OAC.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - March 25, 2020 Category: Cardiology Authors: Louise Kezerle, Meytal Avgil Tsadok, Adi Berliner Senderey, Moshe Hoshen, Maya Leventer ‐Roberts, Orna Reges, Morton Leibowitz, Moti Haim Tags: ORIGINAL ARTICLE Source Type: research

Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry
CONCLUSIONS: Apixaban might be a reasonable alternative to warfarin in patients with severe renal impairment.PMID:34155848
Source: The Israel Medical Association Journal - June 22, 2021 Category: General Medicine Authors: Avishay Elis Robert Klempfner Chen Gurevitz Ela Gilady Ilan Goldenberg Source Type: research

Pages: 1  2  3